Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentabiocel in pediatric IBS
NCT06720805Not yet recruiting
- Sponsor
- Sapienza University of Rome
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Pentabiocel with Placebo (2 arms). Primary endpoint: Fecal Calprotectin Test at 3 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
Pentabiocel
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06720805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720805.